ZA200603596B - 4-Anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) - Google Patents

4-Anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Info

Publication number
ZA200603596B
ZA200603596B ZA200603596A ZA200603596A ZA200603596B ZA 200603596 B ZA200603596 B ZA 200603596B ZA 200603596 A ZA200603596 A ZA 200603596A ZA 200603596 A ZA200603596 A ZA 200603596A ZA 200603596 B ZA200603596 B ZA 200603596B
Authority
ZA
South Africa
Prior art keywords
quinolinecarbonitriles
cml
anilino
treatment
myelogenous leukemia
Prior art date
Application number
ZA200603596A
Other languages
English (en)
Inventor
Frank Charles Boschelli
Jennifer Michele Golas
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200603596(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200603596B publication Critical patent/ZA200603596B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200603596A 2003-11-06 2006-05-05 4-Anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) ZA200603596B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
ZA200603596B true ZA200603596B (en) 2009-12-30

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603596A ZA200603596B (en) 2003-11-06 2006-05-05 4-Anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Country Status (18)

Country Link
US (2) US7417148B2 (enExample)
EP (1) EP1680119A1 (enExample)
JP (1) JP2007533655A (enExample)
KR (1) KR20060118461A (enExample)
CN (1) CN1874776A (enExample)
AU (1) AU2004289243B2 (enExample)
BR (1) BRPI0416289A (enExample)
CA (1) CA2543163A1 (enExample)
CO (1) CO5690608A2 (enExample)
CR (1) CR8350A (enExample)
EC (1) ECSP066548A (enExample)
IL (1) IL175424A0 (enExample)
MX (1) MXPA06004744A (enExample)
NO (1) NO20062255L (enExample)
RU (1) RU2006113691A (enExample)
SG (1) SG146681A1 (enExample)
WO (1) WO2005046693A1 (enExample)
ZA (1) ZA200603596B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
JP5121706B2 (ja) * 2005-06-17 2013-01-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Ｓｒｃキナーゼ阻害薬による溶骨性病変の阻害
BRPI0611977A2 (pt) * 2005-06-24 2010-10-13 Wyeth Corp uso de um composto
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
CA2868899C (en) * 2007-06-01 2017-06-13 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
SG11201705767PA (en) 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US12398355B2 (en) 2019-04-09 2025-08-26 Massachusetts Institute Of Technology Micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Also Published As

Publication number Publication date
US20100029677A1 (en) 2010-02-04
AU2004289243B2 (en) 2010-07-22
NO20062255L (no) 2006-08-01
MXPA06004744A (es) 2006-07-05
RU2006113691A (ru) 2007-12-20
CR8350A (es) 2006-10-06
US20050101780A1 (en) 2005-05-12
WO2005046693A1 (en) 2005-05-26
ECSP066548A (es) 2006-10-17
AU2004289243A1 (en) 2005-05-26
CN1874776A (zh) 2006-12-06
JP2007533655A (ja) 2007-11-22
CO5690608A2 (es) 2006-10-31
IL175424A0 (en) 2008-04-13
CA2543163A1 (en) 2005-05-26
SG146681A1 (en) 2008-10-30
KR20060118461A (ko) 2006-11-23
BRPI0416289A (pt) 2007-01-23
EP1680119A1 (en) 2006-07-19
US7417148B2 (en) 2008-08-26
US7919625B2 (en) 2011-04-05

Similar Documents

Publication Publication Date Title
EP1689485A4 (en) CARDIOELECTROMAGNETIC TREATMENT
EP1638508A4 (en) SHUNT FOR GLUCKOM TREATMENT
EP1749827A4 (en) ANTITUMOR AGENTS
ZA200408767B (en) Immunoconjugates for the treatment of tumours
GB0326486D0 (en) Combination treatment
ZA200603596B (en) 4-Anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
GB0312407D0 (en) Treatment
EP1536719A4 (en) TABLE
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
AU154131S (en) Table
GB2405789B (en) Patient table
AU154258S (en) Game table
AU154608S (en) Game table
AU2003291245A8 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
AP2956A (en) Parasiticidal composition
GB2404587B (en) Parasiticidal composition
EP1365033A4 (en) MOLECULAR DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA
PT1590046T (pt) Composição para o tratamento de hiv ou sida
IL175689A0 (en) Enoxaparin for the treatment of cancer
HK1086761A (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
GB0313630D0 (en) Compositions for the enhanced treatment of depression
GB0316502D0 (en) The structure of exotic panties
AU157684S (en) Router table
GB0327493D0 (en) Treatment medicament
AU157347S (en) Treatment table